Anxiety disorders are a group of mental health conditions characterized by excessive fear, worry, or apprehension that is disproportionate to circumstances and persists over time. Clinically, the core feature is not mere nervousness, but maladaptive threat anticipation accompanied by cognitive, emotional, and physiological symptoms that impair functioning. The neurobiology of anxiety involves coordinated dysregulation across corticolimbic and brainstem networks. The amygdala plays a central role in threat detection and salience processing, while the prefrontal cortex—particularly medial and ventrolateral regions—normally exerts top-down control over threat-related responses. In anxiety disorders, reduced inhibitory control and altered connectivity can bias the individual toward interpreting ambiguous cues as dangerous.
At the neurochemical level, several systems contribute. GABAergic inhibitory signaling is often implicated in impaired anxiolysis and heightened physiological arousal. Glutamatergic transmission can amplify threat learning and persistent worry loops. Serotonergic and noradrenergic pathways modulate mood and arousal; hyperactivity in noradrenergic signaling is consistent with somatic symptoms such as tachycardia, hypervigilance, and insomnia. Stress-response physiology further links anxiety to dysregulated hypothalamic–pituitary–adrenal axis activity, with downstream effects on cortisol patterns and autonomic regulation. These biological influences interact with learning processes: individuals may develop maladaptive threat conditioning, safety-signal reliance, and distorted probability estimates that sustain anxiety over time.
Diagnostic frameworks distinguish anxiety disorders by symptom profiles and temporal patterns. Generalized anxiety disorder (GAD) involves excessive, difficult-to-control worry occurring more days than not for at least several months, accompanied by restlessness, fatigue, impaired concentration, irritability, muscle tension, and sleep disturbance. Panic disorder is marked by recurrent unexpected panic attacks—sudden surges of intense fear with palpitations, sweating, trembling, shortness of breath, chest discomfort, dizziness, and fear of losing control or dying—followed by persistent concern or behavioral change. Social anxiety disorder features marked fear of social or performance situations due to negative evaluation. Specific phobias involve circumscribed fear responses to particular objects or situations, while agoraphobia centers on fear of situations where escape might be difficult or help unavailable.
A key clinical concept is cognitive bias. Many patients exhibit attentional bias toward threat, interpret ambiguous sensations as catastrophic, and engage in worry-based avoidance. Worry can function as an emotion-regulation strategy, briefly reducing distress by simulating control, but paradoxically it maintains anxiety through attentional capture and elimination of corrective learning. In addition, interoceptive conditioning—learning threat meanings from bodily sensations—can perpetuate panic and related symptoms.
Evidence-based treatment typically combines psychotherapy, pharmacotherapy, and lifestyle interventions. First-line psychotherapy for most anxiety disorders is cognitive-behavioral therapy (CBT), including cognitive restructuring and exposure-based techniques. Exposure helps extinguish conditioned fear by repeatedly confronting avoided cues in a controlled manner, reducing fear through new learning rather than suppression. For GAD, CBT often incorporates worry exposure, intolerance-of-uncertainty training, and problem-solving. For panic disorder, CBT emphasizes interoceptive exposure to catastrophic misinterpretations of bodily sensations. Mindfulness-based approaches and acceptance strategies may also help by reducing experiential avoidance.
Pharmacotherapy is commonly used when symptoms are severe, chronic, or refractory to therapy. Selective serotonin reuptake inhibitors (SSRIs) and serotonin–norepinephrine reuptake inhibitors (SNRIs) are first-line medications, as they target serotonergic and noradrenergic modulation of anxiety circuits. Therapeutic benefit generally emerges after several weeks due to neuroadaptation. Benzodiazepines can provide rapid symptom relief through GABA-A receptor potentiation, but they carry risks of sedation, cognitive impairment, tolerance, dependence, and withdrawal; therefore, they are often reserved for short-term bridging or specific circumstances. For refractory cases, augmentation strategies may include specialized pharmacologic regimens under careful monitoring.
Clinicians should also address comorbidities and contributors that worsen anxiety. Depression, substance use, sleep disorders, thyroid dysfunction, and medication side effects can mimic or exacerbate anxiety symptoms. Substance-related anxiety may arise from stimulants, cannabis effects, alcohol withdrawal, or excessive caffeine intake. Sleep hygiene, regular physical activity, and circadian stabilization improve autonomic balance and reduce baseline arousal. Stress management—including structured relaxation, breathing interventions, and problem-focused coping—can complement core treatment.
Risk assessment includes evaluating functional impairment, suicidality in comorbid depression, and medical rule-outs for panic-like symptoms. Treatment planning should be individualized, incorporating patient preferences, prior treatment responses, and safety considerations. Prognosis is favorable for many patients when evidence-based care is initiated early, with sustained remission possible through continued skills practice and relapse-prevention planning.
Source: BusinessToday Malaysia (@BusinessTodayM1, June 25, 2026)
BusinessToday Malaysia: Bursa Malaysia opened largely unchanged, with the FBM KLCI edging lower in early trade as weakness in energy counters offset mild gains across broader market indices.. #breaking
— @BusinessTodayM1 May 1, 2026
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
